Savara’s $100M offering; New biotech to test Eisai drug in Ph2

Plus, news about Daiichi Sankyo, Seagen, Lantheus, Life Molecular Imaging, Astellas Gene Therapies, Eli Lilly and Aparito:

Savara prices $100M offering: The Langhorne, PA-based biotech will secure funds from Bain Capital Life Sciences, Farallon Capital Management, Frazier Life Sciences and others days after announcing Phase 3 data for its rare lung disease drug. — Kyle LaHucik

A new biotech launches with assets from Eisai: Ensho Therapeutics, based in Morris Plains, NJ, plans to start a Phase 2 program in the first half of next year for an oral selective α4β7 inhibitor as part of a licensing deal with Eisai subsidiary EA Pharma. It will enter a category led by Takeda that includes other biotechs like Morphic and Spyre. A spokesperson told Endpoints News that Ensho is…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks